Company Product Description Indication Status
Phase I
Allergan plc, of Dublin, and Editas Medicine Inc., of Cambridge, Mass. AGN-151587 (EDIT-101) CRISPR medicine delivered by subretinal injection Leber congenital amaurosis 10  First patient dosed
Discgenics Inc., of Salt Lake City IDCT Allogeneic, injectable discogenic cell therapy Degenerative disc disease Enrollment completed
Phase II
American Brivision Corp., of Fremont, Calif. ABV-1505 Inhibitor of the norepinephrine transporter Adult attention deficit hyperactivity disorder First patient enrolled
Cytodyn Inc., of Vancouver, Washington Leronlimab CCR5 antagonist  Graft-vs.-host disease First patient treated
Delmar Pharmaceuticals Inc., of San Diego VAL-083 Adjuvant treatment (pre-temozolomide maintenance therapy)  MGMT-unmethylated glioblastoma multiforme Exceeded 50% enrollment in the adjuvant arm
Innovent Biologics Inc., of Suzhou, China Pemigatinib (IBI-375) FGFR1/2/3 inhibitor Advanced cholangiocarcinoma First patient dosed in registrational trial, enrolling patients with FGFR2 fusions or rearrangements who have progressed from at least 1 prior systemic therapy in China
Moderna Inc., of Cambridge, Mass. mRNA-1647 mRNA vaccine Cytomegalovirus Enrollment complete for all 3 dose cohorts; first interim analysis expected in third quarter of 2020
Oncolys Biopharma Inc., of Tokyo, and Chugai Pharmaceutical Co. Ltd., of Tokyo Telomelysin (OBP-301) Genetically modified type 5 adenovirus Locally advanced esophageal cancer Chugai enrolled first patient testing combination with radiotherapy in patients not eligible for surgical excision and definitive chemoradiotherapy
Phase III
Alkermes plc, of Dublin ALKS-3831 Once-daily, oral atypical antipsychotic drug Schizophrenia Data from 4-week Enlighten-1 trial testing ALKS-3831 vs. placebo in 403 patients experiencing acute exacerbation of schizophrenia were published in the Journal of Clinical Psychiatry; drug is under FDA review, with PDUFA date of Nov. 15, 2020

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments